Professional analysis: The therapeutic effect of Opicapone is revealed!

Opicapone is a long-acting COMT inhibitor that delays the degradation of levodopa in peripheral tissues and improves its utilization in the brain, thereby improving the motor symptoms of patients with Parkinson's disease (PD), especially the "off period" phenomenon. The unique feature of this drug is its once-daily long-acting effect. Compared with traditional COMT inhibitors, it reduces the number of daily medication doses and improves patient medication compliance.

Clinical studies have shown that Opicapone can reduce the average daily "off period" of patients with Parkinson's disease by more than 1 hour, improve symptoms such as bradykinesia, stiffness and tremor, and reduce patients' dependence on levodopa dosage. This effect remains stable during long-term use, and some patients can maintain the effect for more than one year. In addition, opicapone was well tolerated and no serious liver toxicity was observed, significantly better than traditional COMT inhibitors.

In terms of mechanism, Opicapone makes the concentration of levodopa in the blood more stable through highly selective and irreversible COMT inhibition, reducing motor complications caused by fluctuations in blood concentration. This characteristic makes it an important part of the comprehensive treatment of Parkinson's disease, especially for patients with gradually declining efficacy of levodopa and obvious motor fluctuations.

In addition, the clinical data of Opicapone also shows that it is not only better than placebo in improving "off period" symptoms, but also shows a longer-lasting effect than traditional COMT inhibitors such as entacapone, and has a lower incidence of side effects. Common adverse reactions include mild insomnia, hallucinations, and dyskinesia, but they are tolerated by most patients and can be alleviated by adjusting the levodopa dose.

Overall, opicapone shows significant efficacy advantages in the adjuvant treatment of Parkinson's disease. When doctors use this drug, they need to closely monitor the patient's clinical response and rationally adjust the dose of levodopa to achieve the best therapeutic effect.

Reference materials:https://www.ongentys.com/